文献速递肝病

非酒精性脂肪性肝病患者的酒精使用与心血管疾病风险

Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease.
PubMed 文献 · Gastroenterology · 2017-08-09

基于CARDIA前瞻性队列中570例非酒精性脂肪性肝病患者,评估酒精使用与心血管疾病风险因素及亚临床心血管疾病指标的关系。多变量调整后,酒精使用与糖尿病、高血压、高脂血症及冠状动脉钙化、E/A比值、整体纵向应变均无关联。与一般人群不同,酒精使用可能不降低非酒精性脂肪性肝病患者的心血管疾病风险。

要点

  • 在非酒精性脂肪性肝病患者中,饮酒与不饮酒相比,心血管疾病风险因素无显著差异。
  • 饮酒与亚临床心血管疾病指标(冠状动脉钙化、E/A比值、整体纵向应变)无关联。
  • 与一般人群不同,酒精使用可能不降低非酒精性脂肪性肝病患者的心血管疾病风险。

核心结论

  • 在中年非酒精性脂肪性肝病人群中,前瞻性评估的酒精使用与心血管疾病风险因素或亚临床心血管疾病标志物无显著差异。
  • 与一般人群研究结果相反,酒精使用可能不降低非酒精性脂肪性肝病患者的心血管疾病风险。

研究设计与样本

  • 分析CARDIA纵向队列研究数据,该队列于1985年至1986年从美国4个城市招募5115名18-30岁黑人和白人年轻成人。
  • 参与者在基线和第15、20、25年自我报告酒精使用情况。
  • 第25年(2010-2011年)进行胸腹部计算机断层扫描和心肌斑点追踪组织多普勒超声心动图检查。
  • 非酒精性脂肪性肝病定义为排除后肝脏衰减值<51亨氏单位。
  • 饮酒者定义为第15、20或25年报告每周1-21标准杯(男性)或1-14标准杯(女性);不饮酒者定义为第15、20和25年均报告无酒精使用。

主要发现

  • 570例非酒精性脂肪性肝病患者(平均年龄50岁;54%黑人;46%女性)中,332例(58%)为饮酒者。
  • 饮酒者中白人、男性及教育水平较高者比例显著高于不饮酒者(P < .05)。
  • 饮酒者中肥胖、糖尿病和代谢综合征比例高于不饮酒者(P < .01)。
  • 两组肝脏衰减值无差异(P = .12)。
  • 多变量调整后,酒精使用与心血管疾病风险因素(糖尿病、高血压、高脂血症)或亚临床心血管疾病指标(冠状动脉钙化、E/A比值、整体纵向应变)无关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Cardiovascular disease (CVD) is the leading cause of death among patients with nonalcoholic fatty liver disease (NAFLD). Moderate drinking (vs abstinence) is associated with lower risk of CVD in the general population. We assessed whether alcohol use is associated with CVD risk in patients with NAFLD. METHODS: We analyzed data from participants in the Coronary Artery Risk Development in Young Adults longitudinal cohort study of 5115 black and white young adults, 18-30 years old, recruited from 4 cities in the United States from 1985 through 1986. Participants self-reported alcohol use at study entry and then again after 15, 20, and 25 years. At year 25 (2010-2011), participants underwent computed tomography examination of the thorax and abdomen and tissue Doppler echocardiography with myocardial strain measured by speckle tracking. Coronary artery calcification was defined as an Agatston score above 0. NAFLD was defined as liver attenuation <51 Hounsfield Units after exclusions. Drinkers reported 1-21 (men) or 1-14 (women) standard drinks/week at years 15, 20, or 25. Nondrinkers reported no alcohol use at years 15, 20, and 25. RESULTS: Of the 570 participants with NAFLD (mean age, 50 years; 54% black; 46% female), 332 (58%) were drinkers; significantly higher proportions of drinkers were white, male, and with higher levels of education compared with nondrinkers (P < .05 for all). Higher proportions of drinkers had obesity, diabetes, and metabolic syndrome compared with nondrinkers (P < .01). There was no difference in liver attenuation between groups (P = .12). After multivariable adjustment, there was no association between alcohol use and CVD risk factors (diabetes, hypertension, hyperlipidemia) or subclinical CVD measures (coronary artery calcification, early transmitral velocity/late (atrial) transmitral velocity (E/A) ratio, global longitudinal strain). CONCLUSIONS: In a population-based sample of individuals with NAFLD in midlife, prospectively assessed alcohol use is not associated with significant differences in risk factors for CVD or markers of subclinical CVD. In contrast to general population findings, alcohol use may not reduce the risk of CVD in patients with NAFLD.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. VanWagner LB, Ning H, Allen NB, et al. Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2017. PMID: 28802566. doi:10.1053/j.gastro.2017.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。